VTVT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

-1.057

+92.12%

-0.910

+18.18%

Estimates Revision

The market is revising No Change the revenue expectations for vTv Therapeutics Inc. (VTVT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 62.72%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+62.72%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 38.00 USD with a low forecast of 36.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

36.00

Averages

38.00

High

40.00

Current: 0.000

Low

36.00

Averages

38.00

High

40.00

TD Cowen

Buy

initiated

$67

2026-01-05

New

Reason

TD Cowen

Price Target

$67

2026-01-05

New

initiated

Buy

Reason

TD Cowen initiated coverage of vTv Therapeutics with a Buy rating and $67 price target. The firm thinks the company's oral hepatoselective glucokinase activator, cadisegliatin will reduce level 2/3 hypoglycemic events and improve HbA1c levels adjunctive to insulin. TD is positive on the topline data due out in the second half of 2026. It models peak sales of $2.15B in 2037.

H.C. Wainwright

Buy

maintain

$36 -> $47

2025-12-19

Reason

H.C. Wainwright

Price Target

$36 -> $47

2025-12-19

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on vTv Therapeutics to $47 from $36 and keeps a Buy rating on the shares to reflect higher conviction in the long-term potential of cadisegliatin for Type 1 diabetes. The firm now models 25% peak market penetration, up from 20% previously, the analyst noted.

BTIG

NULL -> Buy

initiated

$40

2025-11-18

Reason

BTIG

Price Target

$40

2025-11-18

initiated

NULL -> Buy

Reason

BTIG initiated coverage of vTv Therapeutics with a Buy rating and $40 price target. vTv is a clinical-stage biotech company developing oral drugs for metabolic and inflammatory diseases, the analyst tells investors in a research note. The firm expects the company's lead candidate cadisegliatin, a liver selective glucokinase activator in type 1 diabetes, to reduce hypoglycemic events in the Phase 3 CATT1 trial. It projects over $500M in peak sales for cadisegliatin.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Initiates

$36

2025-04-09

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$36

2025-04-09

Initiates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for vTv Therapeutics Inc (VTVT.O) is -10.79, compared to its 5-year average forward P/E of -3.34. For a more detailed relative valuation and DCF analysis to assess vTv Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.34

Current PE

-10.79

Overvalued PE

0.24

Undervalued PE

-6.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.24

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.22

Undervalued EV/EBITDA

-0.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.51

Current PS

0.00

Overvalued PS

69.14

Undervalued PS

-14.12

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VTVT News & Events

Events Timeline

No data

News

6.0

01-05Benzinga

vTv Therapeutics Initiated with Buy Rating and $67 Price Target

6.0

2025-12-24NASDAQ.COM

vTv Therapeutics Upgraded to Zacks Rank #2 (Buy) Reflecting Positive Earnings Outlook

9.0

2025-12-18Globenewswire

vTv Therapeutics Submits Phase 2 Study Protocol for Cadisegliatin in Type 2 Diabetes

People Also Watch

Frequently Asked Questions

What is vTv Therapeutics Inc (VTVT) stock price today?

The current price of VTVT is 35.575 USD — it has decreased -13.36 % in the last trading day.

What is vTv Therapeutics Inc (VTVT)'s business?

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

What is the price predicton of VTVT Stock?

What is vTv Therapeutics Inc (VTVT)'s revenue for the last quarter?

vTv Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is vTv Therapeutics Inc (VTVT)'s earnings per share (EPS) for the last quarter?

vTv Therapeutics Inc. EPS for the last quarter amounts to -1.08 USD, increased 22.73 % YoY.

What changes have occurred in the market's expectations for vTv Therapeutics Inc (VTVT)'s fundamentals?

How many employees does vTv Therapeutics Inc (VTVT). have?

vTv Therapeutics Inc (VTVT) has 23 emplpoyees as of January 10 2026.

What is vTv Therapeutics Inc (VTVT) market cap?

Today VTVT has the market capitalization of 140.10M USD.